论文部分内容阅读
目的:探讨化疗联合贝伐珠单抗治疗老年晚期肺腺癌患者的效果及安全性。方法:回顾性分析2015年1月至2018年9月山东省肿瘤医院199例老年晚期肺腺癌患者资料，其中104例接受化疗联合贝伐珠单抗治疗（联合组），95例接受单纯化疗（化疗组）。评估两组患者的客观反应率（ORR）、疾病控制率（DCR）、总生存（OS）及无进展生存（PFS）。结果:治疗2个周期后第1次评价疗效，联合组部分缓解（PR）42例，疾病稳定（SD）50例，疾病进展（PD）12例，ORR为40.4%（42/104），DCR为88.5%（92/104）；化疗组PR 22例，SD 64例，PD 9例，ORR为23.2%（22/95），DCR为86.9%（86/95）；联合组ORR高于化疗组，差异有统计学意义（n χ2=6.75，n P<0.05）。联合组和化疗组的中位PFS时间分别为7.1个月（95%n CI 6.8～7.5个月）和5.6个月（95% n CI 5.1～6.1个月），差异有统计学意义（n P<0.01）；中位OS时间分别为15.3个月（95%n CI 14.2～16.4个月）和12.4个月（95% n CI 10.8～14.0个月），差异有统计学意义（n P<0.01）。联合组和化疗组≥Ⅲ级不良反应发生率分别为81.7%（85/104）和80.0%（76/95），差异无统计学意义（n χ2=0.10，n P=0.76）。n 结论:老年晚期肺腺癌患者在化疗的基础上加用贝伐珠单抗可以获得更好的预后。“,”Objective:To explore the efficacy and safety of chemotherapy combined with bevacizumab in treatment of elderly patients with advanced lung adenocarcinoma.Methods:The data of 199 elderly patients with advanced lung adenocarcinoma from Shandong Cancer Hospital between January 2015 and September 2018 were retrospectively analyzed. Among them, 104 patients received chemotherapy combined with bevacizumab (the combination group) and 95 patients received chemotherapy alone (the chemotherapy group). The objective response rate (ORR), disease control rate (DCR), overall survival (OS) and progression-free survival (PFS) of the two groups of patients were evaluated.Results:The curative effect was evaluated for the first time after 2 cycles of treatment. In the combined group, 42 cases of partial remission (PR), 50 cases of stable disease (SD), 12 cases of disease progression (PD); ORR was 40.4% (42/104), and DCR was 88.5% (92/104). In the chemotherapy group, 22 cases of PR, 64 cases of SD, 9 cases of PD; ORR was 23.2% (22/95) and DCR was 86.9% (86/95). ORR of the combination group was higher than that of the chemotherapy group, and the difference was statistically significant (n χ2 = 6.75, n P < 0.05). The median PFS time of the combination group and chemotherapy group was 7.1 months (95% n CI 6.8-7.5 months) and 5.6 months (95% n CI 5.1-6.1 months), respectively, and the difference was statistically significant (n P < 0.01). The median OS time was 15.3 months (95% n CI 14.2-16.4 months) and 12.4 months (95% n CI 10.8-14.0 months), and the difference was statistically significant (n P < 0.01). The incidence of ≥ grade Ⅲ adverse reactions in the combination group and chemotherapy group was 81.7% (85/104) and 80.0% (76/95), respectively, and the difference was not statistically significant ( n χ2 = 0.10, n P = 0.76).n Conclusion:The addition of bevacizumab to chemotherapy in elderly patients with advanced lung adenocarcinoma can obtain a better prognosis.